03/10/2000
The surgical products manufacturer has managed to control its costs whilst deriving increasing revenue from its link-up with Genzyme, resulting in improved interim results. In the six months to 30 June, turnover rose from £696,000 to £835,000 with the pre-tax loss being narrowed from £377,000 to £62,000. The company has decided to refocus itself on minimally invasive surgery products and blood products, where there is increasing demand.
| Market cap: | £6.2m |
| PE Average: | 30.6 |
| PE Forecast: | n/a |
| PE Historic: | n/a |
| Share price: | 2.8p |
Related Articles:
|
| 29/03/2001
|
| 28/03/2001
|
| 11/01/2001
|
Development Finance Info
Get info on development finance from 12 engines in 1.
Looking for Development Finance
We have reviewed and sorted 276 odd links for development finance - the top 10 list is presented here..
Development Finance
Looking for Development Finance? Review our comprehensive listings.
